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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: Despite newer TAVR devices and extended labeling, many patients are
still excluded from having TAVR. FDA approval of TAVR resulted in overall in-
crease of both TAVR and SAVR, while the number of patients treated with BAV of
medical therapy continues to decline.
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Background: Although Transcatheter Aortic Valve Implantation (TAVI) has afﬁrmed
as a promising technique guaranteeing similar results to surgical aortic valve replace-
ment (SAVR), long-term data on valve function and clinical outcomes are limited. We
sought to assess 4-year clinical and echocardiographic outcomes in patients undergoing
Transcatheter Aortic Valve Implantation (TAVI) with CoreValve prosthesis.
Methods: Between June 2007 and February 2014, 450 consecutive patients with
symptomatic severe aortic stenosis underwent TAVI using both CoreValve, Edwards-
SAPIEN, and Lotus valves. For the purposes of this study we included only those
patients undergoing successful TAVI with CoreValve prosthesis who had a minimum
follow-up of 4 years (n¼125). All outcomes were deﬁned according to the Valve
Academic Research Consortium (VARC 2).
Results: Survival rates at 1, 2, 3 and 4 years were 83.2, 76.8, 73.6 and 66.3%, respec-
tively. Survival from cardiovascular mortality rates at 1, 2, 3 and 4 years were 88.0,
84.0, 83.2 and 80.8%, respectively. No deaths were directly related to valvular
dysfunction. Freedom from reoperation was 98.5%. We reported satisfactory long-term
valve performance in terms of mean pressure gradients and aortic valve area (AVA).
Echocardiographic follow-up revealed a mean pressure gradients decreasing from
5717.4 mmHg (pre-TAVI) to 10.44.5 mmHg (post-TAVI) (P>0.001) with a small
increase at 1 year (12.486.8 mmHg), which remained steady at 4 years (11.97.1
mmHg). In the majority of cases mild paravalvular regurgitation (PVR) were either
unchanged or slightly improved overtime. Progression frommild acute PVR tomoderate
PVR at 4-year follow-up was reported in three patients. Prosthetic valve failure was
reported in 4 patients (3.2%). Valve thrombosis or late valve embolization were not
reported.
Conclusions: Our study demonstrated that favorable outcomes after successful TAVI
are associated with sustained clinical and functional cardiovascular beneﬁts up to
4-year follow-up. Signs of moderate prosthetic valve failure are present only in a small
percentage of patients.TCT-730
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Background: There is limited information on 5-year outcome of patients undergoing
transcatheter aortic valve implantation. In particular, long-term results of a non-
metallic inﬂatable valve design have never been reported. The aim of the present study
was to evaluate the 5-year clinical and echocardiographic outcome of the ﬁrst gen-
eration retrievable and repositionable 22F Direct Flow Medical Valve percutaneous
aortic valve.
Methods: From 2007 to 2008, 31 symptomatic high-risk for surgery patients (mean
age 824y) with severe aortic stenosis and a mean logistic EuroSCORE of 297%
were the enrolled in this study. Clinical, echocardiographic and hemodynamic follow-
up were obtained during 5 years.
Results: Survival rates were 81%, 69%, 60%, 54%, and 54% at 1,2,3,4, 5 years,
respectively. At 5 years, all surviving patients were NYHA-class I. Echocardiography
revealed a signiﬁcant decrease in the mean gradient from baseline (49.113.8 mmHg)
to 30 days (19.16.8 mmHg) and remained stable over 5 years (15.36.0 mmHg) (p
¼ NS). At 5-year follow-up, aortic regurgitation assessed by TTE was either trace or
none in all patients.
Conclusions: In this preliminary series of , the ﬁrst generation of the nonmetallic,
repositionable and retrievable 22F Direct Flow Medical valve resulted in the acute
hemodyananmic performance was and sustained stable hemodynamic performance
over 5 years including with no or trace aortic regurgitation in the majority of all
patients.
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Background: Elderly patients with severe aortic stenosis and numerous cardiac and
non-cardiac comorbidities are currently considered for transcatheter aortic valve im-
plantation (TAVI). TAVI is effective in alleviating valve-related symptoms and
restoring quality of life. However, many patients remain frail and in a vulnerable
clinical condition after successful TAVI. The aim of this study was to assess rates and
reasons for rehospitalization within one year after TAVI.
Methods: Between August 2007 and September 2012, 549 consecutive patients with
degenerative aortic stenosis underwent TAVI using different access routes and devices
and were included into a prospective registry. Active follow-up was scheduled at 30
days, 6 months and 1 year. All hospital readmissions were ascertained and major
adverse events were adjudicated according to the VARC2 standardized endpoint
deﬁnitions.
Results: Of 549 patients undergoing TAVI, 529(96.4%) were alive at the end of the
index hospitalization and discharged. Of these, 138(26.1%) patients were readmitted
within 1 year of discharge and included in the present analysis. Patients with at least
one readmission had presented with higher logistic EuroScore (25.116 vs.
22.113mmHg,p¼0.01), higher systolic pulmonary artery pressure (55.519 vs.
50.216mmHg,p¼0.02), lower left ventricular ejection fraction (49.016 vs.
53.314mmHg, p¼0.009) and more frequently had previous myocardial infarction
(21.7% vs. 13%,p¼0.02). Overall, 176 readmissions occurred during the observa-
tional period with a cumulative mean hospital duration of 15.616 days. Among
readmitted patients, 73 patients(41.5%) were re-evaluated for cardiovascular causes
(heart failure 17%, peripheral vascular disease 15%, 2% for valvular heart disease), 22
(13%) for gastrointestinal, 12 (7%) for respiratory and 8 patients (5%) for chronic
kidney disease. Twenty-two patients (13%) received non-cardiac surgery and 8 pa-
tients (5%) were found to have a malignant tumor.
Conclusions:Within the ﬁrst year after TAVI, one out of four patients is readmitted to
the hospital. Cardiac causes and vascular disease are among the most frequent reasons
for rehospitalization, while readmission for valve related issues is rare.
TCT-732
Prognostic Value Of Impaired Left Ventricular Function In Patients Undergoing
Transapical Versus Transfemoral Transcatheter Aortic Valve Implantation
(TAVI)
Vincent J. Nijenhuis1, Robin Heijmen2, Martin Swaans2, Thomas de Kroon3,
Jan Van der Heyden4, Jurrien M. Ten Berg5
1St Antonius hospital, Nieuwegein, Netherlands, 2St Antonius Hospital, Nieuwegein,
Netherlands, 3St. Antonius Hospital, Nieuwegein , Netherlands, 4N/A, Nieuwegein,
Netherlands, 5St. Antonius Hospital, Nieuwegein, Netherlands
Background: An impaired left ventricular ejection fraction (LVEF) severely affects
prognosis and peri-operative risk in patients undergoing surgical aortic valve
replacement. Also in patients undergoing TAVI, an impaired LVEF seems to affect
prognosis, although contradictory ﬁndings exist. We analyzed the effects of antember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
Table 1. Univariate Analysis of Hemodynamic Parameters as Predictors of 30
Day Outcomes
N¼120 Pre-TAVR
30 Day
Death or
Readmission
(Prob >ChiSq)
Post-TAVR
Day 1
30 Day
Death or
Readmission
(Prob>ChiSq)
p-Value for
Change in
Hemodynamics
Post TAVR
RAP
(mmHg)
11.6+/-4.22 0.3146 7.36 +/-3.68 0.4608 <0.0001
PASP
(mmHg)
40.4+/-12.3 0.8588 37.2+/-9.55 0.6468 0.0016
PADP
(mmHg)
20.5+/-7.2 0.7086 16.6+/-5.56 0.6529 <0.0001
MPAP
(mmHg)
28.5+/-9 0.8343 23.1+/-6.41 0.9850 <0.0001
CO (L/min) 3.83+/-1.33 0.4437 4.67+/-1.63 0.0482* <0.0001
CI
(L/min/m2)
2.08+/-0.7l 0.6866 2.56 +/-0.9 0.115 <0.0001
PVR
(Woods
units-m2)
2.32+/-2.54 0.8621
TPG
(mmHg)
8.05+/-6.9 0.8969
RVSWI
(mmHg
x mL/m2)
5.46 +/- 4.81 0.2827 6.9 +/- 3.9 0.049* 0.0003
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TAVI.
Methods: All consecutive patients undergoing transfemoral or transapical TAVI in
our centre were prospectively enrolled from June 2007 to December 2013. LVEF was
measured using the Simpson biplane method and classiﬁed as good (50%), moderate
(31-50%), and severely impaired (30%) at transthoracic echocardiography not later
than 3 months before TAVI.
Results: In total, 263 (mean age 81.67.5, male 41.8%, logistic EuroSCORE
23.215.0%) and 224 (mean age 80.06.5, male 46.0%, logistic EuroSCORE
27.416.6%) patients underwent transfemoral and transapical TAVI, respectively. In
the transfemoral group, LVEF was 50%, 31-50%, and 30% in 170 (64.6%), 67
(25.5%) and 26 (9.9%) of patients, respectively. In the transapical group, LVEF was
50%, 31-50%, and 30% in 149 (66.5%), 52 (23.2%) and 23 (10.3%) of patients,
respectively. Thirty-day all-cause mortality was not associated with LVEF. An
impaired LVEF < 50% predicted 2-year mortality for transapical (HR 1.86, 95% CI
1.06 to 3.26, p¼0.03) but not transfemoral TAVI (HR 0.82, 95% CI 0.39 to 1.69,
p¼0.58) after multivariate adjustment.
Conclusions: An impaired LVEF before TAVI affects the prognosis differently per
TAVI approach. The LVEF may be considered in deciding the most appropriate
approach for TAVI.
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Background: The Aortic Valve Academic Research Consortium (VARC) endpoint
deﬁnitions were established to standardize the evaluation of clinical outcomes
following transcatheter aortic valve implantation (TAVI). It remains unclear, however,
to what extent and in which manner these deﬁnitions are used in publications.
Methods:We performed a systematic review of the literature to identify TAVI-related
manuscripts published between Feb. 2011 and Feb. 2014. Two physicians indepen-
dently reviewed these manuscripts and categorized them into 3 groups: a ’compliant’
group comprised of VARC-deﬁned endpoints only, a ’non-compliant’ group
comprised of non-VARC-deﬁned endpoints only, and a ’mixed compliant’ group
comprising VARC- and non-VARC-deﬁned endpoints.
Results: The search yielded a total of 5023 manuscripts and 514 were included in the
analysis. At least one VARC deﬁnition was used in 275 (54%) manuscripts while 223
(43%) did not use any VARC deﬁnitions. We excluded from the analysis 16 (3%)
manuscripts which dealt with outcomes not deﬁned in VARC. Of the manuscripts
using VARC, 49 (10%) were classiﬁed as compliant and 226 (46%) as mixed
compliant. The following endpoints were more often deﬁned using VARC vs. non-
VARC: MI (64% vs 36%), stroke (56% vs. 44%), bleeding and (79% vs 21%)
vascular complications (70% vs. 30%), AKI (63% vs. 37%), reintervention (67% vs.
33%) and composite endpoints (52% vs. 48%). The following endpoints were less
often deﬁned using VARC vs. non-VARC: mortality (59% vs 41%), valve-dysfunc-
tion (82% vs. 18%), TAVI-related complications (59% vs. 41%), NYHA (73% vs.
27%) and QOL (91% vs. 9%). After publication of the ﬁrst VARC manuscript, VARC
usage in TAVI publications increased from 29% at 6 months to 59% at 30 months.
After publication of the revised VARC deﬁnitions VARC-2 usage increased from 3%
at 6 months to 27% at 18 months, while VARC usage in general remained at 54%.
Conclusions: Although VARC deﬁnitions are well accepted within the “community”,
usage in peer-reviewed manuscripts remains suboptimal. Further studies are warranted
to better understand how to improve compliance and adapt these ﬁndings in future
VARC iterations.
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Background: Right ventricular function and pulmonary hypertension are often not
taken into consideration in the prognostication of patients undergoing TAVR;
accordingly their impact on patients undergoing TAVR remains relatively poorly
deﬁned. We sought to explore their effect on 30 day outcomes in patients undergoing
TAVR.
Methods: We collected complete baseline demographic and hemodynamic data ob-
tained by right heart catheterization on 120 consecutive patients undergoing TAVR at
our institution over a 1 year period. 30 day rate of death or hospital readmission were
then examined. Statistical calculations were performed using JMP software.
Results: There were 5 deaths and 5 readmissions within 30 days. Mean age was 82.8
+/-8.2 years, BSA 1.82 +/-0.26m2, STS score 8.14 +/- 5.53, aortic valve area (AVA)
0.63+/-0.16cm2, mean gradient 50.4+/-13.7mmHg, creatinine 1.37+/-0.82 mg/dL,
MELD score 10.4+/-4.3, and length of stay 5.5+/-4.5 days. 61.7% were female, 84.2%JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Vahypertensive, 34.2% diabetic, and 74.2% had coronary artery disease. 63.3% pro-
cedures were transfemoral (TF), 33.3% transapical (TA), and 3.3% trans-aortic (Tao).
Trends toward higher event rates were seen with higher STS scores, lower pre-operative
AVA, mean gradients, left ventricular ejection fraction (LVEF),cardiac output (CO),
cardiac index (CI) or that had TA access. Low post-operative CO and right ventricular
stroke work index (RVSWI) were associated with statistically signiﬁcant higher 30 day
mortality and readmission rates. Pre- or post-operative right atrial pressure (RAP),
pulmonary capillary wedge pressue (PCWP), trans-pulmonary gradient (TPG), pul-
monary vascular resistence (PVR), creatinine, and MELD score had no effect (Table 1).Conclusions: TAVR results in statistically signiﬁcant improvements in most hemo-
dynamic parameters. Poor post-TAVR CO and RVSWI were the strongest hemody-
namic parameters of death or readmission after 30 days.
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Background: Signiﬁcant aortic regurgitation (AR), in particular paravalvular AR,
remains a relevant complication in patients undergoing transcatheter aortic valve
implantation (TAVI) for symptomatic aortic stenosis. It remains unknown whether
postdilatation (PD) as a treatment for paravalvular AR after TAVI improves AR and
interferes with clinical outcome. The aim of this study was to investigate the impact of
PD to reduce paravalvular AR after TAVI and its potential relevance for long-term
survival.
Methods: 416 patients underwent TAVI at our institution from 2008-2013 using
balloon-expandable Edwards Sapien and Sapien XT prostheses. 406 pts were avail-
able for complete retrospective analyses. The severity of paravalvular AR was eval-
uated by procedural angiography and, in a subgroup of patients, also with
echocardiography 7d and 1 y after TAVI. Decision to postdilate or not was made by
the team of implanting physicians immediately after valve deployment. The severity
of AR for these analyses was evaluated by investigators blinded to the outcome.
Results: At a median follow-up of 308d (IQR 92-670), a total of n¼143 deaths
occurred, 30d mortality was 7.9% (n¼32). 54.2% were treated via transfemoral (30d
mortality 4.1%), 33.7% transapical (30d mortality 14.6%) and 12.1% transaortic ac-
cess (30d mortality 6.1%). Mean age was 81.4y (6.15), 56.7% were females, the
mean log. EuroScore was 27.5% (17.3). PD was carried out in n¼137/406 pts
(33.7%) and led to a signiﬁcant reduction of paravalvular AR (Chi-square test p<
0.001). Of note, PD was not associated with increased complications according to
VARC-2 criteria (including new pacemaker, p¼0.66, and periprocedural stroke
p¼0.55, Irwin-Fisher Test). A signiﬁcant postprocedural AR (> grade 1+) was
associated with a worse prognosis in the total n¼406 cohort (HR 1.69, CI 1.1-2.5).
Conclusions: These ﬁndings indicate that PD of ballon-expandable TAVI valves is a
safe and efﬁcient method to reduce paravalvular AR. In addition, this study shows that
pts undergoing PD do not have an inferior prognosis as expected according their initial
AR (p¼0.302). Further investigations will address the long-term follow-up including
AR and durability of postdilated valves.lvular disease - Aortic: TAVR B215
